Elanco Animal Health Incorporated (NYSE:ELAN) delivered strong financial performance for the second quarter of 2026, driven by robust demand across its Pet Health portfolio and expanding margins.
The momentum led management to raise its full-year growth outlook.
The pet health company reported adjusted earnings of 34 cents, beating the consensus of 27 cents.
Zenrelia And Credelio Quattro Gain Traction Sales jumped 10% year-over-year on a reported basis (+8% on constant currency) to $1.368 billion, better than the consensus of $1.313 billion.
Growth was headlined by the Pet Health segment, which increased 12% reported to $718 million.
